<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002572</url>
  </required_header>
  <id_info>
    <org_study_id>93-0426.cc</org_study_id>
    <secondary_id>UCHSC-COMIRB-93426</secondary_id>
    <secondary_id>NCI-T94-0065O</secondary_id>
    <nct_id>NCT00002572</nct_id>
  </id_info>
  <brief_title>Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent Brain Tumors</brief_title>
  <official_title>Intracavitary Allogenic Cytotoxic T Lymphocytes and Human Recombinant Interleukin-2 Therapy for Recurrent Primary Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapy uses different ways to stimulate the immune system and stop&#xD;
      cancer cells from growing. Cytotoxic T cells combined with interleukin-2 may be an effective&#xD;
      treatment for recurrent brain tumors.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of cytotoxic T cells and interleukin-2 in&#xD;
      treating adults with recurrent brain tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Evaluate the toxicity of allogeneic cytotoxic T lymphocytes (CTL) when&#xD;
      repeatedly instilled directly into the brain to treat recurrent primary brain tumors. II.&#xD;
      Evaluate the response produced by allogeneic CTL and interleukin-2. III. Correlate CTL&#xD;
      surface phenotype and degree of patient/donor HLA mismatch to response and toxicity.&#xD;
&#xD;
      OUTLINE: Surgery plus Biological Response Modifier Therapy. Tumor resection; plus&#xD;
      intracavitary cytotoxic T lymphocytes, CTL; intracavitary Interleukin-2 (Chiron), IL-2,&#xD;
      NSC-373364. CTL are generated in vitro by mixing irradiated patient lymphocytes (cultured&#xD;
      with IL-2 and Monoclonal Antibody OKT 3, MOAB OKT 3, NSC-618843) with allogeneic lymphocytes&#xD;
      and culturing the mixture with IL-2.&#xD;
&#xD;
      PROJECTED ACCRUAL: 10 patients will be treated. If severe toxicity occurs in the first 5&#xD;
      patients, the study will close.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1994</start_date>
  <completion_date type="Actual">December 1999</completion_date>
  <primary_completion_date type="Actual">December 1999</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>muromonab-CD3</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic tumor infiltrating lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Kernohan Grade III/IV primary malignant brain tumor that has&#xD;
        failed conventional surgical resection and radiotherapy Evidence of recurrent tumor on&#xD;
        gadolinium-enhanced MRI following completion of radiotherapy (minimum 5,000 cGy for adults)&#xD;
        required The following histologies are eligible: Anaplastic astrocytoma Anaplastic&#xD;
        oligodendroglioma Glioblastoma multiforme Mixed anaplastic glioma Surgical resection of&#xD;
        progressing brain tumor feasible No evidence of tumor extending across the midline from one&#xD;
        hemisphere to the other No multifocal tumor or leptomeningeal spread&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: Karnofsky 60-100% Life&#xD;
        expectancy: At least 2 months Hematopoietic: WBC greater than 2,000 Platelets greater than&#xD;
        100,000 Hct at least 28% Hepatic: Bilirubin less than 1.5 mg/dl Renal: Creatinine less than&#xD;
        1.5 mg/dl Cardiovascular: No major cardiovascular problems Pulmonary: No major pulmonary&#xD;
        problems Other: Seronegative for HTLV/HIV, syphilis, and hepatitis B and C No concurrent&#xD;
        systemic infection Ability to maintain proper nutrition (orally or intravenously) during&#xD;
        the study period required No pregnant women&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: More than 4 weeks&#xD;
        since systemic chemotherapy (6 weeks since carmustine), with the WBC increasing on 2&#xD;
        consecutive determinations at least 3 days apart Endocrine therapy: Not specified&#xD;
        Radiotherapy: At least 8 weeks since radiotherapy Surgery: See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin O. Lillehei, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Health Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2000</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>July 28, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2004</study_first_posted>
  <last_update_submitted>May 28, 2013</last_update_submitted>
  <last_update_submitted_qc>May 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Muromonab-CD3</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

